Investor Cormorant Global Healthcare Master Fund, LP
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Cormorant Global Healthcare Master Fund, LP . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-07-22 13D/A BMEA / Biomea Fusion, Inc. 3,590,949 3,681,664
2024-02-05 13G CRBP / Corbus Pharmaceuticals Holdings, Inc. 1,475,000
2023-07-03 13G/A PRAX / Praxis Precision Medicines, Inc. 9,500,000
2023-06-08 13D US39536G1058 / GREENLIGHT BIOSCIENCES HOLDINGS PBC A 9,188,659
2023-05-01 13G/A EYPT / EyePoint Pharmaceuticals, Inc. 3,200,000
2023-04-03 13D/A BMEA / Biomea Fusion, Inc. 3,172,478 3,590,949
2023-02-14 13G/A EWTX / Edgewise Therapeutics, Inc. 3,565,901 2,946,887
2023-02-14 13G/A RAIN / Rain Enhancement Technologies Holdco, Inc. 1,937,801 2,733,977
2022-02-14 13G/A RAIN / Rain Enhancement Technologies Holdco, Inc. 1,832,653 1,937,801
2022-02-14 13G/A EWTX / Edgewise Therapeutics, Inc. 2,590,914 3,565,901
2021-05-18 13G EWTX / Edgewise Therapeutics, Inc. 2,590,914
2021-05-07 13G RAIN / Rain Enhancement Technologies Holdco, Inc. 1,832,653
2021-04-30 13D BMEA / Biomea Fusion, Inc. 3,172,478
2017-11-07 13G OMER / Omeros Corporation 1,960,000 2,450,000
2017-02-03 13G/A NERV / Minerva Neurosciences, Inc. 1,145,043 1,752,946
2016-03-17 13G VTAE / Vitae Pharmaceuticals, Inc. 1,435,000
2016-03-04 13G ZYNE / Zynerba Pharmaceuticals Inc 475,035
2016-02-26 13G YMTX / Yumanity Therapeutics Inc 1,725,460
2016-02-16 13G/A APTO / Aptose Biosciences Inc. 1,081,867
2016-02-16 13G/A REPH / Societal CDMO Inc 780,000
2016-02-16 13G/A AKTX / Akari Therapeutics, Plc - Depositary Receipt (Common Stock) 0
2016-02-16 13G/A QTNT / Quotient Ltd 1,519,100
2016-02-16 13G/A ARDX / Ardelyx, Inc. 1,481,075
2016-02-16 13G/A NERV / Minerva Neurosciences, Inc. 1,824,206 1,145,043
2016-02-16 13G/A HRTX / Heron Therapeutics, Inc. 1,990,000 1,685,719
2016-02-16 13G/A EGRX / Eagle Pharmaceuticals, Inc. 810,000 400,000
2016-02-16 13G/A SRNE / Sorrento Therapeutics, Inc. 1,945,334 2,095,334
2016-02-16 13G/A GNVC / GenVec, Inc. 1,176,235
2015-09-28 13G OMER / Omeros Corporation 1,960,000
2015-08-28 13G HRTX / Heron Therapeutics, Inc. 1,990,000
2015-08-07 13G IL0011177958 / Intec Pharma Ltd 800,000
2015-05-26 13G SRNE / Sorrento Therapeutics, Inc. 1,945,334
2015-03-23 13G EGRX / Eagle Pharmaceuticals, Inc. 810,000
2015-03-23 13G NERV / Minerva Neurosciences, Inc. 1,824,206
2015-02-17 13G/A ARDX / Ardelyx, Inc. 1,053,500
2015-02-17 13G/A REPH / Societal CDMO Inc 700,000
2014-12-31 13G ARDX / Ardelyx, Inc. 952,000
2014-12-04 13G QTNT / Quotient Ltd 1,500,000
2014-11-24 13G CLTX / Celsus Therapeutics 3,000,000